With $46m, i2o Takes Up The Challenge Of Winning Approval For ITCA 650

The Boston biotech raises series A cash and succeeds Intarcia as the sponsor of the GLP-1 drug/device combination product for type 2 diabetes, subject of two FDA complete response letters.